ω-3 PUFAs ameliorate liver fibrosis and inhibit hepatic stellate cells proliferation and activation by promoting YAP/TAZ degradation

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zhang, Kun ^a   Chang, Yanan ^a   Shi, Zhemin ^a   Han, Xiaohui ^a   Han, Yawei ^a   Yao, Qingbin ^a   Hu, Zhimei ^a   Cui, Hongmei ^a   Zheng, Lina ^a   Han, Tao ^a,b,c   Hong, Wei ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN THIRD CENTRAL HOSPITAL   (China)

^c Tianjin Key Laboratory of Artificial Cell   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OMEGA 3 FATTY ACID; PHOSPHOPROTEIN; PROTEASOME; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TAZ PROTEIN, MOUSE; TRANSCRIPTION FACTOR; YAP PROTEIN, MOUSE;

ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DOWN REGULATION; DRUG EFFECTS; HEPATIC STELLATE CELL; LIVER; LIVER CIRRHOSIS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN DEGRADATION; TREATMENT OUTCOME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FATTY ACIDS, OMEGA-3; HEPATIC STELLATE CELLS; LIVER; LIVER CIRRHOSIS; MALE; MICE, INBRED BALB C; PHOSPHOPROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 84979640327     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep30029     Document Type: Article

References (50)

1. Friedman, S. L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiological reviews 88, 125-172, doi: 10.1152/physrev.00013.2007 (2008).
2. Bataller, R., Brenner, D. A. Liver fibrosis. Journal of Clinical Investigation 115, 209-218, doi: 10.1172/jci200524282 (2005).
3. Friedman, S. L. Molecular Regulation of Hepatic Fibrosis, an Integrated Cellular Response to Tissue Injury. Journal of Biological Chemistry 275, 2247-2250, doi: 10.1074/jbc.275.4.2247 (2000).
4. Herrmann, J., Gressner, A. M., Weiskirchen, R. Immortal hepatic stellate cell lines: useful tools to study hepatic stellate cell biology and function Journal of cellular and molecular medicine 11, 704-722, doi: 10.1111/j.1582-4934.2007.00060.x (2007).
5. Chen, J. et al. Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts. Circulation 123, 584-593, doi: 10.1161/CIRCULATIONAHA.110.971853 (2011).
6. Oh, D. Y. et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142, 687-698, doi: 10.1016/j.cell.2010.07.041 (2010).
7. Swanson, D., Block, R., Mousa, S. A. Omega-3 fatty acids EPA and DHA: health benefits throughout life. Advances in nutrition 3, 1-7, doi: 10.3945/an.111.000893 (2012).
8. Maehre, H. K., Jensen, I. J., Elvevoll, E. O., Eilertsen, K. E. omega-3 Fatty Acids and Cardiovascular Diseases: Effects, Mechanisms and Dietary Relevance. International journal of molecular sciences 16, 22636-22661, doi: 10.3390/ijms160922636 (2015).
9. DEliseo, D., Velotti, F. Omega-3 Fatty Acids and Cancer Cell Cytotoxicity: Implications for Multi-Targeted Cancer Therapy. Journal of clinical medicine 5, doi: 10.3390/jcm5020015 (2016).
10. Dyall, S. C. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Frontiers in aging neuroscience 7, 52, doi: 10.3389/fnagi.2015.00052 (2015).
11. Nobili, V. et al. Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. Plos one 9, e88005, doi: 10.1371/journal.pone.0088005 (2014).
12. Depner, C. M., Philbrick, K. A., Jump, D. B. Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr(-/-) mouse model of western diet-induced nonalcoholic steatohepatitis. The Journal of nutrition 143, 315-323, doi: 10.3945/jn.112.171322 (2013).
13. Kajikawa, S. et al. Eicosapentaenoic acid attenuates progression of hepatic fibrosis with inhibition of reactive oxygen species production in rats fed methionine-and choline-deficient diet. Digestive diseases and sciences 56, 1065-1074, doi: 10.1007/s10620-010-1400-5 (2011).
14. Nemoto, N. et al. Ethyl-eicosapentaenoic acid reduces liver lipids and lowers plasma levels of lipids in mice fed a high-fat diet. In vivo 23, 6 (2009).
15. Anakk, S. et al. Bile acids activate YAP to promote liver carcinogenesis. Cell reports 5, 1060-1069, doi: 10.1016/j.celrep.2013.10.030 (2013).
16. Hiemer, S. E., Szymaniak, A. D., Varelas, X. The transcriptional regulators TAZ and YAP direct transforming growth factor betainduced tumorigenic phenotypes in breast cancer cells. The Journal of biological chemistry 289, 13461-13474, doi: 10.1074/jbc. M113.529115 (2014).
17. Perra, A. et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. Journal of hepatology 61, 1088-1096, doi: 10.1016/j.jhep.2014.06.033 (2014).
18. Yimlamai, D. et al. Hippo pathway activity influences liver cell fate. Cell 157, 1324-1338, doi: 10.1016/j.cell.2014.03.060 (2014).
19. Zhao, B. et al. TEAD mediates YAP-dependent gene induction and growth control. Genes, development 22, 1962-1971, doi: 10.1101/gad.1664408 (2008).
20. Paradis, V. et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 34, 738-744, doi: 10.1053/jhep.2001.28055 (2001).
21. Kobayashi, H. et al. Connective tissue growth factor and progressive fibrosis in biliary atresia. Pediatric surgery international 21, 12-16, doi: 10.1007/s00383-004-1254-z (2005).
22. Chen, L. et al. Epigenetic regulation of connective tissue growth factor by MicroRNA-214 delivery in exosomes from mouse or human hepatic stellate cells. Hepatology 59, 1118-1129, doi: 10.1002/hep.26768 (2014).
23. Chen, L., Charrier, A. L., Leask, A., French, S. W., Brigstock, D. R. Ethanol-stimulated differentiated functions of human or mouse hepatic stellate cells are mediated by connective tissue growth factor. Journal of hepatology 55, 399-406, doi: 10.1016/j. jhep.2010.11.025 (2011).
24. Williams, E. J. G. M., Brigstock, D. R., Arthur, M. J., Benyon, R. C. Increased expression of connective tissue growth factor in fibrotic human liver and in activated hepatic stellate cells. Journal of hepatology 32, 7 (2000).
25. Gressner, A. M., Breitkopf, K. W. R., Dooley, S. Roles of TGF-beta in hepatic fibrosis. Frontiers in Bioscience 1, 15 (2002).
26. Varelas, X. et al. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nature cell biology 10, 837-848, doi: 10.1038/ncb1748 (2008).
27. Hu, M. et al. Notch signaling regulates col1alpha1 and col1alpha2 expression in airway fibroblasts. Experimental biology and medicine 239, 1589-1596, doi: 10.1177/1535370214538919 (2014).
28. Chaulk, S. G., Lattanzi, V. J., Hiemer, S. E., Fahlman, R. P., Varelas, X. The Hippo pathway effectors TAZ/YAP regulate dicer expression and microRNA biogenesis through Let-7. The Journal of biological chemistry 289, 1886-1891, doi: 10.1074/jbc. C113.529362 (2014).
29. Mori, M. et al. Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer. Cell 156, 893-906, doi: 10.1016/j.cell.2013.12.043 (2014).
30. Yu, F. X., Guan, K. L. Transcription and processing: multilayer controls of RNA biogenesis by the Hippo pathway. The EMBO journal 33, 942-944, doi: 10.1002/embj.201488329 (2014).
31. Mannaerts, I. et al. The Hippo pathway effector YAP controls mouse hepatic stellate cell activation. Journal of hepatology 63, 679-688, doi: 10.1016/j.jhep.2015.04.011 (2015).
32. Machado, M. V. et al. Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease. Journal of hepatology 63, 962-970, doi: 10.1016/j.jhep.2015.05.031 (2015).
33. Gurda, G. T. et al. The use of Yes-associated protein expression in the diagnosis of persistent neonatal cholestatic liver disease. Human pathology 45, 1057-1064, doi: 10.1016/j.humpath.2014.01.002 (2014).
34. Park, M. et al. Tonsil-derived mesenchymal stem cells ameliorate CCl4-induced liver fibrosis in mice via autophagy activation. Scientific reports 5, 8616, doi: 10.1038/srep08616 (2015).
35. Mitra, A. et al. IL-30 (IL27p28) attenuates liver fibrosis through inducing NKG2D-rae1 interaction between NKT and activated hepatic stellate cells in mice. Hepatology 60, 2027-2039, doi: 10.1002/hep.27392 (2014).
36. Bansal, R., van Baarlen, J., Storm, G., Prakash, J. The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis. Scientific reports 5, 18272, doi: 10.1038/srep18272 (2015).
37. Xu, L. et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 54, 142-151, doi: 10.1136/gut.2004.042127 (2005).
38. MadanKumar, P., NaveenKumar, P., Manikandan, S., Devaraj, H., NiranjaliDevaraj, S. Morin ameliorates chemically induced liver fibrosis in vivo and inhibits stellate cell proliferation in vitro by suppressing Wnt/beta-catenin signaling. Toxicology and applied pharmacology 277, 210-220, doi: 10.1016/j.taap.2014.03.008 (2014).
39. Ruy, P. T. Is cirrhosis of the liver experimentally produced by CCl4 and adequate model of human cirrhosis Hepatology 3, 8 (1983).
40. Calviello, G. et al. Docosahexaenoic acid induces proteasome-dependent degradation of beta-catenin, down-regulation of survivin and apoptosis in human colorectal cancer cells not expressing COX-2. Carcinogenesis 28, 1202-1209, doi: 10.1093/carcin/bgl254 (2007).
41. Zhao, H. et al. Pulmonary delivery of docosahexaenoic acid mitigates bleomycin-induced pulmonary fibrosis. BMC Pulmonary Medicine 14, 10 (2014).
42. Kim, Y. Transcriptional Activation of Transforming Growth Factor beta 1 and its Receptors by the Kruppel-like Factor Zf9/Core Promoter-binding Protein and Sp1. POTENTIAL MECHANISMS FOR AUTOCRINE FIBROGENESIS IN RESPONSE TO INJURY. Journal of Biological Chemistry 273, 33750-33758, doi: 10.1074/jbc.273.50.33750 (1998).
43. Wang, C. et al. Differences in Yes-associated protein and mRNA levels in regenerating liver and hepatocellular carcinoma. Molecular medicine reports 5, 410-414, doi: 10.3892/mmr.2011.640 (2012).
44. Dong, J. et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130, 1120-1133, doi: 10.1016/j. cell.2007.07.019 (2007).
45. Camargo, F. D. et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Current biology: CB 17, 2054-2060, doi: 10.1016/j.cub.2007.10.039 (2007).
46. Liu, F. et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am J Physiol Lung Cell Mol Physiol 308, 14, doi: 10.1152/ajplung.00300.2014.-Pathological (2015).
47. Hudert, C. A. et al. Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proceedings of the National Academy of Sciences of the United States of America 103, 11276-11281, doi: 10.1073/pnas.0601280103 (2006).
48. Kang, J. X., Wang, J. A simplified method for analysis of polyunsaturated fatty acids. BMC biochemistry 6, 5, doi: 10.1186/1471-2091-6-5 (2005).
49. Folch, J., Lees, M., Sloane Stanley, G. H. A simple method for the isolation and purification of total lipides from animal tissues. The Journal of biological chemistry 226, 497-509 (1957).
50. Maschmeyer, P., Flach, M., Winau, F. Seven steps to stellate cells. Journal of visualized experiments : JoVE, doi: 10.3791/2710 (2011).